OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity. 2014

Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Generation of functional dendritic cells (DCs) with boosted immunity after the withdrawal of initial activation/maturation conditions remains a significant challenge. In this study, we investigated the impact of a newly developed maturation cocktail consisting of OK-432 and interferon-gamma (IFN-γ) on the function of human monocyte-derived DCs (MoDCs). We found that OK-432 plus IFN-γ stimulation could induce significantly stronger expression of surface molecules, production of cytokines, as well as migration of DCs compared with OK-432 stimulation alone. Most importantly, DCs matured with OK-432 plus IFN-γ-induced maintained secretion of interleukin-12 (IL-12)p70 in secondary culture after stimulus withdrawal. Functionally, OK-432 plus IFN-γ-conditioned DCs induce remarkable Th1 and Tc1 responses more effectively than OK-432 alone, even more than the use of α-type-1 cytokine cocktail. As a result, DCs matured with OK-432 plus IFN-γ can prime stronger cytotoxic lymphocyte (CTL) and natural killer (NK) cell response against tumor cells in vitro. Peripheral blood mononuclear cells activated by DCs matured with OK-432 plus IFN-γ also showed greater tumor growth inhibition in vivo in null mice. Molecular mechanistic analysis showed that DC maturation using IFN-γ in concert with OK-432 involves the activation of p38 and nuclear factor-kappa B (NF-κB) pathways. This study provided a novel strategy to generate more potent immune segments in DC vaccine.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010844 Picibanil A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity. NSC-B116209,OK-432,Picibanyl,Streptococcal OK-432,Streptococcal Preparation OK-432,NSC B116209,NSCB116209,OK 432,OK432,Streptococcal OK 432,Streptococcal OK432,Streptococcal Preparation OK 432,Streptococcal Preparation OK432
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug

Related Publications

Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
November 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
July 2021, Clinical cancer research : an official journal of the American Association for Cancer Research,
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
April 1987, The Japanese journal of experimental medicine,
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
April 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
May 2018, Cellular & molecular immunology,
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
January 2005, Anticancer research,
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
April 2014, Cancer immunology, immunotherapy : CII,
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
April 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
January 1990, Biotherapy (Dordrecht, Netherlands),
Ke Pan, and Lin Lv, and Hai-xia Zheng, and Jing-jing Zhao, and Qiu-zhong Pan, and Jian-jun Li, and De-sheng Weng, and Dan-dan Wang, and Shan-shan Jiang, and Alfred E Chang, and Qiao Li, and Jian-chuan Xia
June 1987, The Japanese journal of experimental medicine,
Copied contents to your clipboard!